News

Soliris effective for myasthenic crisis in 4 patients in China

Treatment with Soliris (eculizumab) was effective for managing myasthenic crisis in four people with myasthenia gravis (MG) at a center in China, a study reported. “[Soliris] exhibited a tolerable and efficacious profile in treating patients with [myasthenic crisis],” the researchers wrote, adding that “larger sample sizes and longer…

Experimental cell therapy KYV-101 wins RMAT designation for MG

Kyverna Therapeutics’ experimental cell therapy, KYV-101, has been granted regenerative medicine advanced therapy (RMAT) status by the U.S. Food and Drug Administration (FDA) for treating progressive myasthenia gravis (MG). RMAT designation is intended to expedite the development and FDA review of experimental regenerative treatments that treat, modify, reverse,…

Phase 3 IMVT-1402 trial advancing in plans, with March as goal

By March, Immunovant plans to initiate four or five pivotal clinical trials of its lead therapeutic candidate IMVT-1402 across a range of autoimmune conditions, including myasthenia gravis (MG). Pivotal, or registrational, trials are large-scale studies whose data could support regulatory applications seeking a therapy’s approval. Immunovant announced…

Anti-malaria drug shows promise in rat model for treating MG

The anti-malaria drug dihydroartemisinin, known simply as DHA, showed promise in a rat model of myasthenia gravis (MG) as a potential treatment for the autoimmune disease, a new study reports. In addition to alleviating many MG-related symptoms, DHA inhibited pro-inflammatory T-cells while boosting immune-suppressing T-regulatory cells. Treatment with the…

Soliris sustains clinical benefit for MG in real-world setting

Soliris (eculizumab) effectively eased symptoms and reduced the need for other medications in adults with myasthenia gravis (MG) in a clinical practice setting, according to two-year data from an observational study called ELEVATE. Findings were reported in the study “United States clinical practice experience with eculizumab in…

Study links hard-to-manage gMG disease symptoms to higher costs

People with generalized myasthenia gravis (gMG) with many hospital visits before diagnosis or hard-to-manage disease symptoms at the time of diagnosis tend to accrue higher healthcare-related costs after getting diagnosed, a new study reports. The use of certain treatments before diagnosis and in the year after, as well…

Thymectomy may ease neurological symptoms in older patients: Study

Surgical removal of the thymus, called a thymectomy, may significantly ease the neurological symptoms of patients older than 65 who have myasthenia gravis (MG) and a thymus tumor, according to a new study from researchers in Italy. Overall, nearly 90% of older individuals undergoing thymectomy showed a neurological…